Literature DB >> 16828920

Latest technologies for the enhancement of antibody affinity.

Kim L Wark1, Peter J Hudson.   

Abstract

High affinity antibodies are crucial both for the discovery and validation of biomarkers for human health and disease and as clinical diagnostic and therapeutic reagents. This review describes some of the latest technologies for the design, mutation and selection of high affinity antibodies that provide a paradigm for molecular evolution of a far wider range of proteins including enzymes. Strategies include both in vivo and in vitro methods and embrace the latest concepts for antibody display and selection. Specifically, affinity enhancement can be tailored to the target-binding surface, typically the complementary determining region (CDR) loops in antibodies, whereas enhanced stability, expression or catalytic properties can be affected by selected changes to the core protein scaffold. Together, these technologies provide a rapid and powerful strategy to drive the next generation of protein-based reagents for numerous clinical, environmental and agribusiness applications.

Entities:  

Mesh:

Year:  2006        PMID: 16828920     DOI: 10.1016/j.addr.2006.01.025

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  16 in total

1.  Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display.

Authors:  Christian Votsmeier; Hanna Plittersdorf; Oliver Hesse; Andreas Scheidig; Michael Strerath; Uwe Gritzan; Klaus Pellengahr; Peter Scholz; Andrea Eicker; David Myszka; Wayne M Coco; Ulrich Haupts
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

2.  Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies.

Authors:  Xiaoling Wang; Tapan K Das; Satish K Singh; Sandeep Kumar
Journal:  MAbs       Date:  2009-05-29       Impact factor: 5.857

3.  Engineering anti-vascular endothelial growth factor single chain disulfide-stabilized antibody variable fragments (sc-dsFv) with phage-displayed sc-dsFv libraries.

Authors:  Yi-Jen Huang; Ing-Chien Chen; Chung-Ming Yu; Yu-Ching Lee; Hung-Ju Hsu; Anna Tung Ching Ching; Hung-Ju Chang; An-Suei Yang
Journal:  J Biol Chem       Date:  2010-01-12       Impact factor: 5.157

4.  High-affinity lamprey VLRA and VLRB monoclonal antibodies.

Authors:  Satoshi Tasumi; C Alejandro Velikovsky; Gang Xu; S Annie Gai; K Dane Wittrup; Martin F Flajnik; Roy A Mariuzza; Zeev Pancer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-22       Impact factor: 11.205

Review 5.  Contributions of immunoaffinity chromatography to deep proteome profiling of human biofluids.

Authors:  Chaochao Wu; Jicheng Duan; Tao Liu; Richard D Smith; Wei-Jun Qian
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-01-12       Impact factor: 3.205

6.  Automated screening of monoclonal antibodies for SISCAPA assays using a magnetic bead processor and liquid chromatography-selected reaction monitoring-mass spectrometry.

Authors:  Regine M Schoenherr; Lei Zhao; Jeffrey R Whiteaker; Li-Chia Feng; Li Li; Lina Liu; Xiuwen Liu; Amanda G Paulovich
Journal:  J Immunol Methods       Date:  2009-12-01       Impact factor: 2.303

7.  A microfluidic device for multiplexed protein detection in nano-liter volumes.

Authors:  Alan H Diercks; Adrian Ozinsky; Carl L Hansen; James M Spotts; David J Rodriguez; Alan Aderem
Journal:  Anal Biochem       Date:  2008-12-24       Impact factor: 3.365

8.  Quantitative selection and parallel characterization of aptamers.

Authors:  Minseon Cho; Seung Soo Oh; Jeff Nie; Ron Stewart; Michael Eisenstein; James Chambers; Jamey D Marth; Faye Walker; James A Thomson; H Tom Soh
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

9.  Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.

Authors:  Marcus P Kelly; F-T Lee; Kiki Tahtis; Barbara E Power; Fiona E Smyth; Martin W Brechbiel; Peter J Hudson; Andrew M Scott
Journal:  Cancer Biother Radiopharm       Date:  2008-08       Impact factor: 3.099

10.  A mechanistic PK/PD model for two anti-IL13 antibodies explains the difference in total IL-13 accumulation observed in clinical studies.

Authors:  Abhinav Tiwari; Marion Kasaian; Anne C Heatherington; Hannah M Jones; Fei Hua
Journal:  MAbs       Date:  2016-04-06       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.